Medicines Development For Global Health

This study tested a single dose of moxidectin in 36 children aged 4 to 17 years who have or are at risk of onchocerciasis (river blindness). The goal was to find a dose for children 4 to 11 years that works as well as the 8 mg dose used in older people. Researchers measured drug …

This study tested the safety of a single dose of moxidectin compared to ivermectin in nearly 13,000 people living in areas with river blindness (onchocerciasis). Some participants also received albendazole for a related infection. The goal was to see if moxidectin causes fewer or…